Navigation Links
BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/17/2009

ting loss of $10.9 million in 2007.

Non-GAAP net income was $7.2 million, or $0.19 per diluted share, in 2008 compared to a net loss of $9.0 million, or $0.32 per share, in 2007. On a GAAP basis, the Company reported a net loss of $3.4 million in 2008, compared to $11.6 million in 2007.

Balance Sheet

As of December 31, 2008, the Company had cash and cash equivalents of $15.7 million and notes receivable of $15.8, totaling $31.5 million. Notes receivables are notes accepted from customers for the settlement of trade receivable balances. All notes receivables are guaranteed by established banks in China and have maturities of six months or less.

Financial Guidance

As previously announced, for the fiscal year 2009, revenue is anticipated to increase at least 35% year over year to reach $150 to $160 million.

The Company announced today that it expects EBITDA for the full year 2009 to reach $16 million to $18 million.

The Company is also adjusting its 2009 net income guidance to reflect interest costs and debt discount amortization related to newly issued convertible debt due in July 2011. The Company expects GAAP net income to be between $2 million and $4 million and expects non-GAAP net income to be between $9 million and $11 million.

David Gao, Chief Executive Officer of BMP Sunstone, stated, "We expect 2009 to be another record year for our Company, with revenue growth of over 35% at the low end of our guidance range. We are actively transforming BMP Sunstone from a low margin distribution business into a high margin OTC and prescription specialty pharmaceutical company, and our guidance for 2009 reflects a more mature, diversified company with significant ability to drive shareholder value."

Gao continued, "Our 2009 financial guidance reflects sales and marketing expansion in China resulting from continued performance
'/>"/>

SOURCE BMP Sunstone Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BMP Sunstone to Present at UBS Global Healthcare Services Conference
2. BMP Sunstone Adopts Voluntary Executive Compensation Restrictions in 2008 and 2009
3. BMP Sunstone Receives High Tech Status
4. BMP Sunstone to Present at the 20th Annual Piper Jaffray Health Care Conference
5. BMP Sunstone Acquires Runchang Capsule and Related LFHC Technology
6. BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesdays Call
7. BMP Sunstone Reports Third Quarter 2008 Financial Results
8. BMP Sunstone Announces Participation in November Investor Conferences
9. BMP Sunstone Announces Participation in September Investor Conference
10. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
11. BMP Sunstone Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... WriteResult, a premier provider of ePRO technologies ... School of Public Health and New Haven Farms to ... month-long project. The goal of the study was to ... free access to fresh produce and nutrition education on ... high blood pressure, diabetes and weight gain. Patients completed ...
(Date:3/25/2015)... 2015 Optimal Research, LLC has been nominated ... Award "Best Clinical Site or Trial Network". ... been selected as a nominee in this ViE award ... Recommended" distinction in 2014. The ViE awards were created ... and positive contributions of companies and individuals in the ...
(Date:3/25/2015)... -- Accelovance, a therapeutically focused contract research organization (CRO), ... Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards ... This is the eighth consecutive year Accelovance has been ... "Best Contract Research Organization" in 2009, 2010, and 2011, ... "We,re excited to be a finalist for the ...
(Date:3/25/2015)... San Francisco, CA (PRWEB) March 25, 2015 ... Provide Support for Novel Mechanism of Action in ... March 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) ... its fast skeletal muscle troponin activator tirasemtiv in ... from a Phase IIa “Evidence of Effect” or ...
Breaking Biology Technology:Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6
... 4 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... company in the People,s Republic,of China, today announced ... its common stock which will begin trading under ... Genesis, common stock will no longer trade,under the ...
... Shandong, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ --,China Biologic ... Biologic",or the "Company"), one of the leading ... China (the "PRC"), today announced that on,August ... Drug Administration (the "SFDA"),granted China Biologic,s production ...
... EDMONTON, Sept. 4 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today,announced that the Food and ... fast track designation for the Company,s lead drug, ... (SPMS). Dirucotide,(MBP8298) is currently being evaluated in a ...
Cached Biology Technology:Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 2Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 3China Biologic's Production Facility Renews GMP Certification 2China Biologic's Production Facility Renews GMP Certification 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... and Shenzhen, China, September 30, 2013 - China,s genomics ... the initiation of a joint project to unravel the ... of over $900k, the project will be one of ... involve experts from the IPATIMUP, a leading cancer research ...
... Pace recognizes that we are at a critical time in ... decrease in new HIV infections worldwide and increasing numbers of ... and vaccine research and new evidence on Treatment as Prevention, ... Sharon Lewin, Local Co-Chair of AIDS 2014, Head of the ...
... the human body, particularly neuroproteins that maintain proper brain ... and Parkinson,s are known as "tangle diseases" because they ... in the brain. A team of Australian and ... BMAA can be inserted into neuroproteins, causing them to ...
Cached Biology News:New mechanism for protein misfolding may link to ALS 2
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
... Mouse polyclonal antibody raised against ... Immunogen: SLC22A3 ... a.a) partial recombinant protein with ... Accession Number: NM_021977 ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
Biology Products: